IRIS
CORTELLINI, ALESSIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.761
NA - Nord America 751
SA - Sud America 522
EU - Europa 348
AF - Africa 31
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.418
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.882
US - Stati Uniti d'America 710
CN - Cina 426
BR - Brasile 419
VN - Vietnam 199
HK - Hong Kong 159
IT - Italia 93
DE - Germania 55
AR - Argentina 44
FI - Finlandia 28
GB - Regno Unito 28
NL - Olanda 28
AT - Austria 25
EE - Estonia 25
MX - Messico 24
EC - Ecuador 22
ID - Indonesia 22
IN - India 21
ZA - Sudafrica 18
UA - Ucraina 16
PY - Paraguay 12
CA - Canada 10
FR - Francia 10
BD - Bangladesh 9
CO - Colombia 7
ES - Italia 7
JP - Giappone 7
RU - Federazione Russa 7
PE - Perù 6
SE - Svezia 6
CL - Cile 5
TR - Turchia 5
AU - Australia 3
KE - Kenya 3
KZ - Kazakistan 3
NP - Nepal 3
VE - Venezuela 3
AZ - Azerbaigian 2
BO - Bolivia 2
CH - Svizzera 2
IE - Irlanda 2
IQ - Iraq 2
MA - Marocco 2
PH - Filippine 2
PK - Pakistan 2
PL - Polonia 2
RO - Romania 2
SI - Slovenia 2
SN - Senegal 2
UY - Uruguay 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
BY - Bielorussia 1
BZ - Belize 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
GA - Gabon 1
GH - Ghana 1
GR - Grecia 1
GT - Guatemala 1
HN - Honduras 1
HU - Ungheria 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
KH - Cambogia 1
LB - Libano 1
LU - Lussemburgo 1
MY - Malesia 1
NC - Nuova Caledonia 1
NG - Nigeria 1
NO - Norvegia 1
OM - Oman 1
PS - Palestinian Territory 1
QA - Qatar 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TW - Taiwan 1
Totale 6.418
Salva come PNG Salva come JPEG
Città #
Dallas 289
Singapore 283
Hefei 193
Hong Kong 158
Beijing 124
Ashburn 105
Ho Chi Minh City 76
Boardman 54
Hanoi 41
São Paulo 40
Council Bluffs 38
Shanghai 28
Munich 25
Amsterdam 21
Rome 20
Turku 19
London 18
Sona 15
Los Angeles 14
Mexico City 14
Santa Clara 14
Da Nang 11
Rio de Janeiro 11
Vienna 11
Brooklyn 9
Guayaquil 9
Johannesburg 9
Milan 9
New York 9
Belo Horizonte 8
Brasília 8
Curitiba 8
Jinan 8
Salvador 8
Goiânia 7
Helsinki 7
Hải Dương 7
Thái Bình 7
Guarulhos 6
Haiphong 6
Sorocaba 6
Boston 5
Caxias do Sul 5
Cordova 5
Kolkata 5
Maceió 5
San Francisco 5
Santo André 5
Seattle 5
Stockholm 5
Asunción 4
Biên Hòa 4
Blumenau 4
Can Tho 4
Chennai 4
Chicago 4
Florence 4
Hortolândia 4
Joinville 4
Nuremberg 4
Phủ Lý 4
Quito 4
Recife 4
Ribeirão Preto 4
Tokyo 4
Ankara 3
Bogor 3
Bình Dương 3
Cape Town 3
Carapicuíba 3
Chernivtsi 3
Dhaka 3
Durban 3
Durham 3
Jacareí 3
Lima 3
Limeira 3
Manaus 3
Medellín 3
Modena 3
Monte Grande 3
Montes Claros 3
Montreal 3
Nairobi 3
Nola 3
Piracicaba 3
Pune 3
Resistencia 3
Santiago 3
São Bernardo do Campo 3
São Gonçalo 3
Teresina 3
Wesley Chapel 3
Anyang 2
Aparecida de Goiânia 2
Baku 2
Balsas 2
Barbacena 2
Barra Bonita 2
Barro 2
Totale 1.956
Salva come PNG Salva come JPEG
Nome #
1338P TP53 truncating and missense mutations are linked to differential response to checkpoint blockade in patients with advanced non-small cell lung cancer (NSCLC) 281
1065P Dose dependent detrimental effect of baseline pantoprazole on clinical outcomes from first-line chemo-ICI regimens in patients with advanced stage NSCLC 253
112P Measuring time-toxicity and prognostic impact of hospital attendance in early phase cancer trials participants 248
1352P Real-world second-line outcomes of NSCLC patients receiving first-line chemotherapy plus immunotherapy 246
A preliminary study on the diagnostic performance of the uPath PD-L1 (SP263) artificial intelligence (AI) algorithm in patients with NSCLC treated with PD-1/PD-L1 checkpoint blockade 219
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 215
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research 214
Beyond clinical trials: real-world impact of immunotherapy on NSCLC in Jordan 212
69P Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors 210
A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 207
Clinical implications of the family history in patients with lung cancer: a systematic review of the literature and a new cross-sectional/prospective study design (FAHIC: lung) 207
Association of Survival With Immune-Related Adverse Events—Time to Consider the Duration of Treatment 205
96P Induction chemotherapy backbone in frail patients (pts) with advanced NSCLC treated with chemotherapy plus pembrolizumab (P): A single institution retrospective audit of dose intensities from modified regimens 203
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 200
P3.13C.09 First-Line Treatments for Advanced Pure Large Cell Neuroendocrine Tumors (LCNEC):Insights from a Global Clinico-Genomic Study 196
Early opioid exposure (EOE) and impaired efficacy in patients with advanced NSCLC treated with PD-L1 inhibition: A pooled post hoc analysis of the POPLAR and OAK trials 187
534 Determinants of 5-year survival in patients with advanced NSCLC with PD-L1 ≥50% treated with first line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry 110
485 Impact of opioid signaling on the tumor microenvironment and clinical outcomes in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) 104
THU-464 aMAP score predicts progression-free survival in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 98
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 97
Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis 95
OS-078-YI Hepatic decompensation as an aetiology-dependent determinant of mortality in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab 95
Clinical outcomes and post-progression retreatment in patients with metastatic NSCLC who complete two years of treatment with immune checkpoint blockade 91
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation 81
T.07.3: CHARACTERISTICS AND OUTCOMES OF IMMUNOTHERAPYRELATED LIVER INJURY IN PATIENTS WITH HEPATOCELLULAR CARCINOMA COMPARED TO PATIENTS WITH ADVANCED SOLID TUMOURS 77
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 69
Association of Obesity With Survival Outcomes in Patients With Cancer 65
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer 54
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study 44
Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study) 43
S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models 42
Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study 41
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 41
Beyond environmental risk: Genetic insights into lung cancer susceptibility through whole exome analysis 40
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 39
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 38
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry 38
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index 38
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 38
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 37
Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes 37
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 37
Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials 36
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 35
Safety and Efficacy of Osimertinib in Patients With Non–Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis 34
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study 33
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study 32
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival 32
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 32
Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice 32
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 32
Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: An INVIDIa-2 study sub-analysis 32
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 31
The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden 30
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC 30
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652–3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal Cancer 30
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study 29
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer 29
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice 29
Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation 29
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors 28
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer 28
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromes 28
Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post‐hoc analysis of the phase I/III IMpower 133 trial 28
Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival 27
Diabetes and Immune Checkpoint Inhibitors—Response 27
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 27
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction 27
The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A "hypothesis-generator' study from clinical practice 27
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 26
Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study 26
Glycemic control and cancer outcomes in oncologic patients with diabetes: an Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE), Italian Society of Pharmacology (SIF) multidisciplinary critical view 25
The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma 24
Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry 24
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 23
Impact of Neoadjuvant Immune Checkpoint Inhibitors on Surgery and Perioperative Complications in Patients With Non-small-cell Lung Cancer: A Systematic Review 23
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 23
Increased interleukin-6/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer 23
COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management 22
Efficacy and safety of frontline systemic therapy for advanced HCC: A network meta-analysis of landmark phase III trials 21
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries 21
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study 21
Induction chemotherapy backbone in frail patients with advanced NSCLC treated with chemotherapy plus pembrolizumab: a single institution retrospective audit of dose intensities from modified regimens 20
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 20
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab 20
Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registry 20
Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 20
Immunotherapy in Hepatocellular Carcinoma 19
Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry 19
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 19
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers 19
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 19
Circulating receptor activator of nuclear factor kappa-B ligand (RANKL) levels predict response to immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) 17
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 16
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 16
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians' attitudes 16
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 12
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity 9
Hierarchical embedding attention for overall survival prediction in lung cancer from unstructured EHRs 8
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors 8
Totale 6.505
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.243
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.243
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202227 0 0 0 0 3 0 0 0 4 0 0 20
2022/20232 0 0 0 0 1 0 0 0 0 0 1 0
2023/2024102 0 10 19 14 7 29 2 3 6 5 5 2
2024/20254.356 26 19 72 19 12 30 148 64 244 276 1.793 1.653
2025/20262.025 298 215 512 637 253 110 0 0 0 0 0 0
Totale 6.512